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It was reported that IL-17 had been detected in the inflammatory infiltrates of patients with DM (dermatomyositis). In this study, we
investigated the frequency of Th17 cells and the expression of microRNA-206 (miR-206) in DM patients. Firstly, we observed that
the frequency of Th17 cells and the expression of transcription factors were increased significantly in the PBMCs of DM patients.
Secondly, we found that there was a positive correlation between the percentages ofTh17 cells and serum level of CK inDMpatients.
And the serum concentrations of IL-6, IL-1𝛽, TGF-𝛽, and IL-23, the important cytokines ofTh17 differentiation, were increased in
DMpatients. It was predicted that Kru¨ppel-like factor 4 (KLF4) is one of themultiple targets ofmiR-206.We detected the expression
of miR-206 in DM patients, and it was decreased in the serum and PBMCs of DM patients. The augmented expression of KLF is
accompanied by the attenuated expression of miR-206. Furthermore, a negative correlation between the percentages of Th17 cells
and the expression of miR-206 in DM patients has been found. Taken together, these findings suggest the attenuated expression of
miR-206, and the augmented frequency of Th17 cells in DM patients.
1. Introduction
DM (dermatomyositis) is a subtype of inflammatory
myopathies, which is a rare autoimmune disease of skeletal
muscle. Patients with DM typically experience the symmetric
proximal muscle weakness, electromyographic and muscle
alteration, characteristic skin lesion, and elevation of
muscle enzymes such as creatine kinase (CK) or lactate
dehydrogenase (LDH). Therefore, these clinical symptoms
are current diagnostic criteria for DM [1, 2].
Although the pathogenic mechanism of DM is still
unclear, it was considered as a CD4+T cells driven disease
[3, 4]. On the basis of cytokine expression, CD4+ helper
T cells were classified into Th1, Th2, regulatory T cells,
and Th17 cells [5]. Early study demonstrated that Th17
cells participate in host defense against extracellular bacteria
and fungi. Furthermore, it was observed that Th17 cells
are also involved in the process of several inflammatory
and autoimmune diseases, such as autoimmune arthritis,
Crohn’s disease, multiple sclerosis, psoriasis, andHashimoto’s
thyroiditis [6–12]. Recent study elucidated that some proin-
flammatory cytokines such as IL-6, IL-1𝛽, TGF-𝛽, and IL-23
are critical factors functioning during the process ofTh17 cells
differentiation [13–16].
It was reported that IL-17, a key cytokine of Th17 cells,
had been detected in the inflammatory infiltrates of patients
with DM [17]. And there was a study showed that the
concentration of IL-6, a crucial factor of human Th17 cells
differentiation, was significantly higher in the serum of DM
patients [18]. But there is no study focusing on the alteration
of Th17 cells in the peripheral blood of patients with DM.
In this study we found the proportion of Th17 cells was
augmented in the peripheral blood of patients with DM
compared to healthy controls. The expression of RORC gene,
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a key transcription factor of humanTh17 cells, was enhanced
in the PBMCs (peripheral blood mononuclear cells) of DM
patients. In addition to RORC, Kru¨ppel-like factor 4 (KLF4),
a transcription factor of cell differentiation, tumor suppres-
sion, stem cell properties, and malignant transformation,
is another positive regulator of Th17 differentiation [19–21].
And its expression was enhanced in the PBMCs of DM
patients as expected. Also, compared with healthy controls,
the level of related cytokines increased in the serum of
patients with DM. All the data above suggest that Th17 cells
may play a role in the pathogenesis of DM.
MicroRNAs are a class of small noncoding RNAs that
modulate gene expression at the posttranscriptional level.
They usually bind to the 3󸀠-untranslated regions (UTR) of
mRNAs, inhibiting translation, causing accelerated turnover
or degradation of the mRNA transcript [22]. It was predicted
that KLF4 is one of the multiple targets of miR-206, and an
inverse trend between KLF4 and miR-206 has been validated
in human [23]. Our study verified that the expression of
KLF4 gene was enhanced in the PBMCs, and an attenuated
expression of miR-206 was confirmed in the PBMCs as well
as the plasma of DM patients. These data suggest that Th17
cells may play a role in the pathogenesis of DM.
2. Materials and Method
2.1. Individuals and Samples. Twenty-seven patientswithDM
were included in this study. The diagnosis was based on
commonly accepted classification criteria of Bohan and Peter
[1]. All the patients were on the period of onset of DM at
the time of this study. Main clinical data of these patients
are shown in Table 1. Peripheral blood samples were obtained
from all patients. The serum concentrations of CK and LDH
are abtained by biochemistry test (Beckman au5831, Japan).
Thirty healthy control subjects were included, ranging from
32 to 50 years old (42.73 ± 5.058, data correspond to the
arithmetic mean ± SD of the ages of the control subjects).
All samples were taken in accordancewith the regulations
and approval of the Affiliated People’s Hospital of Jiangsu
University.
2.2. Cell Isolation and Stimulated In Vitro. Peripheral blood
mononuclear cells (PBMCs) were isolated by density-gradi-
ent centrifugation over Ficoll-Hypaque solution. PBMCs
were washed and incubated in complete RPMI 1640 culture
medium in the presence of 50 ng/mL phorbol myristate
acetate (PMA; Sigma-Aldrich St. Louis, MO) and 1.0 𝜇g/mL
ionomycin (Sigma-Aldrich) for 5 h. After 5 h of culture at 37
Cunder 5%CO
2
, cells were collected and centrifuged forTh17
cells and mRNA detection by flow cytometric analysis and
qRT-PCR, respectively.
2.3. Flow Cytometric Analysis. Stimulated PBMCs were
washed and immunostained with phycoerythrin-cy5-conju-
gated anti-CD3 (eBioscience, San Diego, CA), fluores-
cein isothiocyanate-conjugated anti-CD8 (eBioscience, San
Diego, CA), and phycoerythrin- (PE-) conjugated anti-IL-
17 (eBioscience, San Diego, CA) mAb against human cells.
Table 1: Clinical features of DM patients included in the study.
DM Range
n 28
Gender (M/F) 8/20
Age (yr) 52.29 ± 14.09 27–59
LDH (U/L) 438.6 ± 277.7 146.0–1287
CK (U/L) 864.2 ± 1460 24.00–5694
Data correspond to the arithmetic mean ± SD, M: male; F: female.
Isotype-matched Ab controls were used in all procedures.
All the staining was according to manufacturers’ protocol.
Cells were analyzed using a FACSCalibur flow cytometer and
CELLQUEST software (Becton Dickinson, Sparks, MD), and
results were expressed as the percent of CD3+CD8− cells
expressing IL-17.
2.4. RNA Isolation and Real-Time PCR. For the detection
of cytokine IL-17, transcription factor RORC, and KLF4,
PBMCs were stimulated for 5 h as described above. After that
activated cells were used to quantify the expression of IL-17
and RORC mRNA by real-time PCR.
TRIzol reagent (Invitrogen, Carlsbad, CA) was added
in stimulated PBMCs. After isolated total RNA, reverse
transcription was performed according to the manufac-
turer’s instruction (Toyobo, Osaka, Japan). MicroRNA in
plasma was isolated with NucleoSpin:emoji: miRNA Plasma
(Macherey-Nagel, Du¨ren, German). miRNA qRT-PCR Prim-
er Set (Ribo, Guangzhou, China) and M-MLV Reverse Tran-
scriptase (Takara, Dalian, China) were used for miR-206 and
U6 reverse transcription.
Real-time PCR was performed in duplicate using
Bio-Rad SYBR green super mix (Bio-Rad, Hercules,
CA). Primer sequences were as follows: IL-17, sense, 5󸀠-
CAAGACTGAACACCGACTAAG-3󸀠; antisense, 5󸀠-TCT-
CCAAAGGAAGCCTGA-3󸀠, RORC, sense, 5󸀠-CCTGGG-
CTCCTCGCCTGACC-3󸀠; antisense, 5󸀠-TCTCTCTGCCCT-
CAGCCTTGCC-3󸀠, KLF4, sense, 5-CAA GTC CCG CCG
CTC CAT TAC CAA-3; anti-sense, 5-CCA CAG CCG TCC
CAG TCA CAG TGG-3., miR-206, sense, 5-GAGTGCTGG-
AATGTAAGGAAG-3; antisense, 5-GCAGGGTCCGAG-
GTATTC-3.
We used 𝛽-actin or U6 as internal control. Data were
analyzed by Bio-Rad CFX Manager software.
2.5. Cytokine Quantification. Levels of IL-6, IL-1𝛽, TGF-
𝛽, and IL-23 were determined by ELISA (eBioscience, San
Diego, CA) using an ELISA reader (𝜇Quant, BIO-TEK,USA).
All determinations were performed in duplicate, and the
lower detection limits for IL-6, IL-1𝛽, TGF-𝛽, and IL-23 were
1.5625, 1.5625, and 125 pg/mL, 15.625 pg/mL, respectively.
2.6. Statistical Analysis. Student’s unpaired or paired t test
was performed to determine whether there was a statistically
significant change between two groups. Correlations between
variables were determined by Spearman’s correlation coeffi-
cient. Data were analyzed with GraphPad Prism5 software
(GraphPad Software, Inc., San Diego, CA).
Clinical and Developmental Immunology 3
3. Results
3.1. Th17 Lymphocytes in the PBMCS of Patients with DM.
To quantify Th17 cells in peripheral blood of patients with
DM; first we analyzed the proportion of CD3+CD8−IL-
17+lymphocytes in PBMCs ofDMpatients by flow cytometry.
The expression of CD4molecule on PBMCs is downregulated
after being stimulated with PMA and ionomycin, so we
gated on CD3+CD8− in PBMCs and identified IL-17+cells to
distinguish the Th17 cells from activated T cells in PBMCs
(Figure 1(a)). The percentage of Th17 cells was significantly
increased in PBMCs from patients with DM compared with
healthy controls (𝑃 = 0.0007, Figure 1(b)).
qRT-PCR analysis displays an enhanced expression of
IL-17mRNA in the PBMCs from DM patients, with lower
expression in healthy controls (Figure 1(c)).
To further document the state of Th17 cells in DM
patients, we analyzed the expression of RORC and KLF4
mRNA, which plays a considerable role in differentiation of
Th17 cells. As expected, the expression of RORC or KLF4
mRNA in PBMCs from DM patients is significantly higher
than that from healthy controls (Figures 1(d) and 1(e)). In
addition, we found high levels of KLF4 mRNA expression
with increased circulatingTh17 lymphocytes in DM patients,
and there was a modest correlation between the percentages
of Th17 cells and the expression of KLF4 mRNA in PBMCs
from DM patients (𝑟 = 0.6000, 𝑃 = 0.0734) (Figure 1(f)).
These results collectively indicate that the proportion of
Th17 cells in DM patients is augment.
3.2. High Levels of CK with Increased Circulating Th17 Cells
in DM Patients. In patients with DM, the muscle enzymes
such as CK or LDH are upregulated, and they are index of
prognosis for DM. So we analyzed the correlation between
clinical and laboratory parameters. And we found that there
was a positive correlation between the percentages of Th17
cells and serum level of CK (𝑟 = 0.6350, 𝑃 = 0.0265), but not
with the level of LDH (𝑟 = 0.2089, 𝑃 = 0.5147) (Figure 2).
This result demonstrated that the percentage of Th17 cells
could reflect the severity of DM in some extent.
3.3. Serum Levels of Cytokines Related to Th17 Lymphocytes
Differentiation. It was reported that IL-6 and IL-1𝛽 are essen-
tial in the differentiation ofTh17 cells, and some investigators
considered that TGF-𝛽 facilitates the differentiation of Th17
cells. In order to elucidate the influencing factors of Th17
cells enhancement in DM patients, we analyzed the levels
of IL-6, IL-1, TGF-𝛽, and IL-23 in serum from DM patients
and healthy controls. We found that DM patients have
significantly increased serum concentration of IL-6, TGF-𝛽,
and IL-23 in comparison with healthy controls (𝑃 = 0.0011,
𝑃 = 0.0097, and 𝑃 = 0.0031, resp., Figures 3(a), 3(b), and
3(d)). In addition, serum concentrations of IL-1𝛽 are higher
in DM patients compared with healthy controls, but this
difference did not reach statistical significance (Figure 3(c)).
These data suggest that the high level of these related
cytokinesmay promote the augmentation ofTh17 cells in DM
patients.
3.4. Attenuated miR-206 Expression in Patients with DM.
KLF4 plays a considerable role in differentiation ofTh17 cells.
We have certified the augment expression of KLF4 mRNA
in PBMCs of DM patients, and we also found that there
was a modest correlation between the percentages of Th17
cells and the expression of KLF4 mRNA. The inverse trend
between KLF4 and miR-206 has been validated in a previous
study [16], so we detected the expression of miR-206 in
the serum and PBMCs of DM patients by qRT-PCR. As a
result, the expression of miR-206 is significantly attenuated
in the PBMCs and serum of DM patients as compared to
healthy controls (Figures 4(a) and 4(b)). Also, there was a
modest correlation between the expression of miR-206 and
the expression of KLF4 mRNA (𝑟 = −0.7006, 𝑃 = 0.0501)
(Figure 4(c)). Apart from this, a negative correlation between
the percentages of Th17 cells and the expression of miR-206
in PBMCs of 9 DM patients has been found in this study
(𝑟 = −0.9333, 𝑃 = 0.0007) (Figure 4(d)).
These findings suggest that the augmented expression of
KLF4 mRNA may be caused by the attenuated expression
of miR-206, and the high level of KLF4 mRNA evokes the
proportion of Th17 cells in DM patients.
4. Discussion
Dermatomyositis (DM) is an autoimmune myopathies char-
acterized by common muscle weakness and an inflamma-
tory infiltrate in muscle [1]. The conventional and available
treatment of DM patients is intravenous corticosteroid and
immunosuppressive agent. As it is known, long-term use of
corticosteroid and immunosuppressive agent would impact
the immunological balance in patients. But the pathogenesis
of DM is still unclear, and the investigation in this aspect is
limited.Therefore, identification of the involved mechanisms
may provide an important step towards developing therapeu-
tic strategies for DM patients.
DM was considered as a CD4+T cells driven disease [4].
CD4+T cells were defined as Th1, Th2, Treg, and Th17 based
on the profiles of cytokine secretion [5]. It has been demon-
strated that Th17 cells were involved in several autoimmune
diseases. A recent study showed that IL-17-producing cells
have been detected in muscle biopsy from DM patients [17].
And the level of IL-6, the important factor of Th17 cells
differentiation, increased in serum of DM patients compared
with healthy controls [18]. We speculated that there could
be an alteration of Th17 cells in the peripheral blood of
patients with DM. To confirm this hypothesis, we assessed
the proportion of Th17 cells and the expression of IL-17
mRNA in the peripheral blood of 13 patients with DM and
10 healthy controls. We identified CD3+CD8−IL-17+ cells
to distinguish the Th17 cells from PBMCs. As expected,
increased CD3+CD8−IL-17+ cells and enhanced expression
of IL-17mRNAwere found inPBMCs frompatientswithDM.
Recent researches have demonstrated that RORC is a
critical transcription factor of human Th17 cells needed to
orchestrate the differentiation of human Th17 cells [24]. Our
study has found that there was an enhanced expression of
RORC mRNA in PBMCs from DM patients compared with
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Figure 1: Th17 cells in the peripheral blood from DM patients. PBMCs from DM patients and healthy controls were incubated with
PMA/ionomycin, stained for cell surface molecules CD3 and CD8 as well as intracellular IL-17, and analyzed by flow cytometry. (a)
Representative dot plots from DM patient and a control subject are shown. Values correspond to the percentage of Th17 lymphocytes. We
used isotype controls to determine the positive cells, and all the values are gated on the CD3+CD8− cells. (b) Percentages ofTh17 lymphocytes
were compared between DM patients and control subjects. (c) Levels of IL-17 mRNA in PBMCs pretreated with PMA/ionomycin from DM
patients and controls. (d) The levels of RORC mRNA in PBMCs were detected by real-time PCR from DM patients and healthy controls. (e)
The levels of KLF4mRNA in PBMCs were detected by real-time PCR fromDMpatients and healthy controls. (f)The correlation between the
percentages of Th17 lymphocytes and the expression of KLF4 mRNA in PBMCs from DM patients. Each data point represents an individual
subject; horizontal lines show the mean. ∗𝑃 < 0.05; ∗∗𝑃 < 0.01; ∗∗∗𝑃 < 0.001.
control subjects. And we also found that the expression of
KLF4, another critical positive regulator of Th17 differenti-
ation [20], was increased in PBMCs from DM patients. The
data exhibit the enhancement of Th17 cells on mRNA level.
It has been widely accepted that the upregulation of mus-
cle enzymes such asCKandLDH is themost objective clinical
manifestations of DM; it could evaluate the development of
DMand show the prognosis for this disease [25].We analyzed
the correlation between proportion of Th17 cells and level
of muscle enzyme. It was shown that there was a positive
correlation between the percentages of Th17 cells and serum
level of CK, but not with the level of LDH. These results
collectively indicate that the proportion of Th17 cells in DM
patients is augmented and could reflect the severity of DM to
some extent.
To investigate the influential factor of Th17 cells aug-
mentation in DM patients, we detected the proinflammatory
cytokines which are essential for the human Th17 differenti-
ation. In previous researches, IL-6 and IL-1𝛽 were regarded
as the key factors of human Th17 differentiation [14, 15].
But the standpoint about the function of TGF-𝛽 in human
Th17 differentiation is still controversial. Some investigators
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Figure 3: Serum levels of proinflammatory cytokines are increased in DM patients compared with healthy controls. (a) Serum levels of IL-6
were determined by ELISA in serum samples from DM patients and controls. (b) Serum levels of IL-1𝛽 were determined by ELISA in serum
samples from DM patients and controls. (c) Serum levels of TGF-𝛽 were determined by ELISA in serum samples from DM patients and
controls. (d) Serum levels of IL-23 were determined by ELISA in serum samples from DM patients and controls. Horizontal lines show the
mean. ∗∗𝑃 < 0.01; ns: no significant differences.
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Figure 4: Levels of miR-206 were decreased in DM patients compared with healthy controls. (a) Serum levels of miR-206 were determined
by real-time PCR in serum samples from DM patients and controls. (b)The level of miR-206 in PBMCs was detected by real-time PCR from
DM patients and controls. (c)The correlation between the expression of miR-206 and the expression of KLF4mRNA in DM patients. (d)The
correlation between the percentages of Th17 lymphocytes in PBMCs and the expression of miR-206 in DM patients. Horizontal lines show
the mean. ∗𝑃 < 0.05.
considered that TGF-𝛽 facilitated the differentiation of Th17
cells [16], but others sustained the negative function of TGF-
𝛽 in Th17 differentiation [14]. We found that DM patients
had significantly increased serum concentration of IL-6 and
TGF-𝛽 in comparison with healthy controls, and serum
concentration of IL-1𝛽 is higher in DM patients compared
with healthy controls, but this difference did not reach
statistical significance. These results demonstrated that the
augmentation ofTh17 cells in DM patients may be influenced
by the high level of these proinflammatory cytokines.
To further analyze the influential factor of Th17 cells
enhancement in DM patients, we considered searching the
miRNA which may influence the enhancement of Th17 cells.
KLF4 is one of the targets of miR-206, and an inverse
relationship between miR-206 and KLF4 in human has been
confirmed [23]. After acquiring the increased expression
of KLF4 mRNA in PBMCs of DM patients, we verified
the decreased expression of miR-206 in PBMCs and serum of
DMpatients. Apart from these, we found that therewas a high
level of KLF4 expression with decreased miR-206 expression
in PBMCs of DM patients, and the correlation between
expression of KLF4 andmiR-206 inDMpatients’ PBMCswas
modest. Moreover, there was a negative correlation between
the percentages of Th17 cells and the expression of miR-
206 in PBMCs of DM patients. These data manifested that
the augmented expression of KLF4 mRNA may be caused
by the attenuated expression of miR-206, and the high level
of KLF4 mRNA evokes the proportion of Th17 cells in DM
patients.
In summary, our data collectively suggest that there is an
augmented frequency of Th17 lymphocytes in DM patients,
and the attenuated expression of miR-206 may regulate the
percentage of Th17 cells in DM patients to some extent.
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